Clinical Trials Logo

Filter by:
NCT ID: NCT00225147 Completed - Clinical trials for Hereditary Angioedema

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Start date: July 2005
Phase: Phase 2/Phase 3
Study type: Interventional

Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening. "HAE" is caused by mutations in the "C1INH" gene that lead to a decrease in the blood level of functional "C1INH". This multi-center study was designed to assess the safety and tolerability, efficacy, and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor ("rhC1INH") in the treatment of acute hereditary angioedema attacks. Funding Source - FDA OOPD

NCT ID: NCT00225121 Completed - Neoplasms Clinical Trials

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Start date: October 11, 2005
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

NCT ID: NCT00224757 Completed - Stroke Clinical Trials

Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation - TIARA Pilot Study

TIARA
Start date: September 2005
Phase: N/A
Study type: Interventional

In this multi centre pilot study we will perform TEE in patients with AF who are eligible for VKA treatment. TTE will be used as pre-screening: if TTE shows left atrial abnormalities or aortic plaque, patients will be excluded from randomisation. TEE will be performed in all other patients to detect or exclude complex aorta plaques or signs of left atrial stasis. Three hundred patients who do not have these features on TTE will be randomly assigned to treatment with aspirin or VKA. Follow-up will be 1 year.

NCT ID: NCT00224523 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Long Term Safety Of GW685698X Via Nasal Biopsy

Start date: September 2005
Phase: Phase 3
Study type: Interventional

Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal congestion, rhinorrhea and/or nasal itching.

NCT ID: NCT00224510 Completed - Bipolar Disorder Clinical Trials

A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium

Start date: August 2002
Phase: Phase 3
Study type: Interventional

This is a study that, in the first 16 weeks, investigates whether lamotrigine versus placebo offers effect on depressive episodes for patients with bipolar disorder (also known as manic depressive disorder) who use lithium. In the following 50 weeks it is investigated whether these patients experience effect on their depressive and/ or (hypo)manic episodes.

NCT ID: NCT00224484 Completed - Herpes Simplex Clinical Trials

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Start date: April 7, 2004
Phase: Phase 3
Study type: Interventional

Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00224432 Completed - Atopic Dermatitis Clinical Trials

Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis

Start date: March 2001
Phase: N/A
Study type: Interventional

To study the effect of supplementation of a hydrolyzed formula with probiotic bacteria on clinical and immunological parameters in infants with AD with and without CMA and to compare effectiveness of different strains of probiotics.

NCT ID: NCT00223561 Completed - ADHD Clinical Trials

Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder

Start date: February 2003
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to determine the effects of methylphenidate versus placebo on driving ability of adult ADHD patients.

NCT ID: NCT00221052 Completed - Obesity Clinical Trials

Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men

Start date: June 2005
Phase: N/A
Study type: Interventional

Overweight increases the risk to develop chronic diseases including type-2 diabetes and cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects is thought to play an important role in disease development. The purpose of this study is to determine the role of inflammation on glucose metabolism and insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on markers of inflammation and on parameters of glucose metabolism will be studied.

NCT ID: NCT00220272 Completed - Parkinson Disease Clinical Trials

Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

Start date: January 2004
Phase: Phase 2
Study type: Interventional

- The primary objective is to study the effect of SR57667B at the dose of 4 mg/d on progression of dopaminergic nigro-striatal lesions assessed by 18F-Dopa PET imaging. - Secondary objectives are to assess the effect of SR57667B on symptomatic decline in patients with early PD, to assess the safety/tolerability of SR57667B in patients with early PD and to document plasma concentrations of SR57667 in patients with early PD.